Pediatric aspergillosis: Disease and treatment differences in children

Pediatric Infectious Disease Journal

Volumn 24, Issue 4, 2005, Pages 358-364

  Steinbach, William J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspergillosis; Aspergillus; Caspofungin; Galactomannan; Pediatric; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; GALACTOMANNAN; ITRACONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; HUMAN; NEUTROPENIA; NEWBORN DISEASE; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PEDIATRICS;

EID: 17144431756     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000157218.37603.84     Document Type: Review

References (66)

1. Groll AH, Shah PM, Mentzel C, et al. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23-32.
2. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
3. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000;31:1524-1528.
4. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-805.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
6. Denning DW, Marinus A, Cohen J, et al. An EORTC multicenter prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect. 1998;37:173-180.
7. Lin SJ, Schranz J, Teutsch. SM. Aspergillosis case-fatality rate: systemic review of the literature. Clin Infect Dis. 2000;32:358-366.
8. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003; 37(suppl 3):S157-S187.
9. Shaw FW, Warthen HJ. Aspergillosis of bone. South Med J. 1936;29:1070-1071.
10. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicenter survey in the greater Paris area. J Hosp Infect. 2002;51:288-296.
11. Yuen KY, Woo PCY, Ip MSM, et al. Stage-specific manifestations of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis. 1997;25:37-42.
12. Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation: a 7-year single centre investigation of 409 cases. Bone Marrow Transplant. 1999;23:589-597.
13. Fukuda T, Boeckh M, Cater RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827-833.
14. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
15. Benjamin DKJ, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J. 2002;21:227-234.
16. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993, and 1997. Pathol Int. 2003;53:744-750.
17. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus infections in a pediatric hospital: a ten year review. Pediatr Infect Dis J. 1993;12:673-682.
18. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210-1219.
19. Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis. 1998;27:437-452.
20. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis. 2001;20:77-82.
21. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-248.
22. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824-1833.
23. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
24. Muller FMC, Groll AH, Walsh TJ. Current approaches to diagnosis and treatment of fungal infections in children infected with human immunodeficiency virus. Eur J Pediatr. 1999;158:187-199.
25. Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1997;16:216-221.
26. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis. 1994;19(suppl 1):41-48.
27. Drut R, Anderson V, Greco MA, et al. Opportunistic infections in pediatric HIV infection: a study of 74 autopsy cases from Latin America. Pediatr Pathol Lab Med. 1997;17:569-576.
28. Reik RA, Rodriguez MM, Hensley GT. Infections in children with human immunodeficiency virus/acquired immunodeficiency syndrome: an autopsy study of 30 cases in South Florida, 1990-1993. Pediatr Pathol Lab Med. 1995;15:269-281.
29. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi. Am J Med. 1981;71:59-66.
30. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine. 1998;77:345-354.
31. Dotis J, Panagopoulou P, Filioti J, et al. Femoral osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous disease. Infection. 2003;31:121-124.
32. Wilhelm L, McLeary MS, Janner D. MR Diagnosis of pulmonary and chest wall aspergillosis as an initial presentation of chronic granulomatous disease in a 7-month-old male. Pediatr Radiol. 2000;30:719-720.
33. Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis. 2004;8:103-110.
34. Moskaluk CA, Pogrebniak HW, Pass HI, Gallin JI, Travis WD. Surgical pathology of the lung in chronic granulomatous disease. Am J Clin Pathol. 1994;102:684-691.
35. Sallman S, Heilmann A, Heinke F, et al. Caspofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous disease. Pediatr Infect Dis J. 2003;22:199-200.
36. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Crit Care Med. 1998;157:1694-1696.
37. Gefter WB, Albelda SM, Talbot GH, Gerson SL, Cassileth PA, Miller W. Invasive pulmonary aspergillosis and acute leukemia: limitations in the diagnostic utility of the air crescent sign. Radiology. 1985;157:605-610.
38. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol. 2003;33:453-460.
39. Allan BT, Pattern D, Ramsey NKC, Day DL. Pulmonary fungal infections after bone marrow transplant. Pediatr Radial. 1988;18:118-122.
40. Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol. 1993;23:177-180.
41. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol. 1999;37:3223-3228.
42. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002;34:939-943.
43. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol. 2003;41:2184-2186.
44. Bretagne S, Marmorat-Khuong A, Kuentz M, Latge JP, Bart-Delabese E, Cordonnier C. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect. 1997;35:7-15.
45. Ulusakarya A, Chachaty E, Vantelon J-M, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J. 2000;1:111-116.
46. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for galactomannan: early predictive values and clinical use in invasive aspergillosis. Pediatr Infect Dis J. 1996;15:232-237.
47. Chachaty E, Gaillard M, Botterel F, et al.High rate of false positive results of Aspergillus galactomannan enzyme linked immunoenzymatic assay (ELISA) in oncopediatric patients. In: 15th Congress of the International Society for Human and Animal Mycology, May 25-29, 2003, San Antonio, TX.San Antonio, TX:International Society for Human and Animal Mycology; 2003. Abstract 011.
48. McLaughlin L, Mitchell L, Ferrera C, et al. Detection of Aspergillus galactomannan antigne in pediatric serum samples: a performance evaluation of the Boi-Rad Platelia Aspergillus EIA. Paper presented at: Focus on Fungal Infections 13; March 19-21, 2003; Maui, Hawaii. Abstract P-30.
49. Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis. 1996;15:139-145.
50. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002;7:1898-1906.
51. Mennink-Kersten MASH, Klont RR, Warris A, Op den Camp HJM, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet. 2004;363:325-327.
52. Warris A, Abrahamsen TG, Breuker IM, Meis JF, Gaustad P, Verweij PE. Fungal antigenemia in premature neonates due to the presence of galactomannan and mannan in milk formulas. In: 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. Chicago, IL: American Society for Microbiology; 2001. Abstract J-848.
53. Verweij PE, Weemaes CM, Curfs JHAJ, Bretagne S, Meis JFG. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol. 2000;38:3900-3901.
54. Walsh TJ, Schaufele RL, Sein T, et al. Reduced expression of galactomannan antigenemia in patients with invasive aspergillosis and chronic granulomatous disease or Job's syndrome. In: 40th Annual Meeting of the Infectious Diseases Society of America, October 24-27, 2002, Chicago, IL. Alexandria, VA:Infectious Diseases Society of America; 2002. Abstract 345.
55. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359-366.
56. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27:1406-1412.
57. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135-144.
58. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine. 2000;79:250-260.
59. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis. 1990;12:1147-1200.
60. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
61. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-1396.
62. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J. 1999;18:702-708.
63. Cesaro S, Strugo L, Alaggio R, et al. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer. 2003;11:722-727.
64. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966-2001. Clin Infect Dis. 2003;37(suppl 3):S188-S224.
65. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-2172.
66. Walsh TJ,Adamson PC,Seibel NL, et al. Pharmacokinetics of caspofungin in pediatric patients. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002; San Diego, CA.Washington, DC:American Society for Microbiology;2002.Abstract M-896.